Taken together, these data point to a dual mechanism of action for a CD38-targeted AttenukineTM, involving both immune and tumor-directed activity, and highlight the potential benefit of a CD38-targeted attenuated IFNα therapy. This evidence concerns the gene IFNA2 and neoplasm.